**ImmuoCult™ Human CD3/CD28 T Cell Activator**

**Human T cell activation and expansion reagent**

<table>
<thead>
<tr>
<th>Catalog #</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>10971</td>
<td>2 mL</td>
</tr>
<tr>
<td>10991</td>
<td>5 x 2 mL</td>
</tr>
</tbody>
</table>

**Product Description**

ImmuoCult™ Human CD3/CD28 T Cell Activator is designed to activate and expand human T cells in the absence of magnetic beads, feeder cells, or antigen. ImmuoCult™ Human CD3/CD28 T Cell Activator consists of soluble tetrameric antibody complexes that bind CD3 and CD28 cell surface ligands. Binding of the tetrameric antibody complexes results in the cross-linking of CD3 and CD28 cell surface ligands, thereby providing the required primary and co-stimulatory signals for T cell activation. Activated T cells can be expanded in ImmuoCult™-XF T Cell Expansion Medium (Catalog #10981) or other media for culturing human T cells supplemented with cytokines.

- Robust activation and expansion of human T cells without the use of magnetic beads, feeder cells, or antigen
- Provides a gentle activation stimulus that maintains high viability of activated and expanded T cells
- Highly stable, filter-sterilized soluble reagent

**Properties**

- **Storage:** Store at 2 - 8°C.
- **Shelf Life:** Stable until expiry date (EXP) on label.
- **Contains:**
  - Anti-human CD3 monospecific tetrameric antibody complex
  - Anti-human CD28 monospecific tetrameric antibody complex

**Handling / Directions For Use**

NOTE: This is a general protocol for using ImmuoCult™ Human CD3/CD28 T Cell Activator. Depending on the experimental objectives, optimization may be required (e.g. cell seeding density and cytokine concentration) for optimal cell growth.

1. Isolate human T cells from fresh or previously frozen peripheral blood mononuclear cells, or leukapheresis samples, using one of the following EasySep™ kits:
   - EasySep™ Release Human CD3 Positive Selection Kit (Catalog #17751)
   - EasySep™ Human T Cell Enrichment Kit (Catalog #19051)
   - EasySep™ Human T Cell Isolation Kit (Catalog #17951)
   NOTE: Isolated T cells can be cryopreserved using CryoStor® CS5 (Catalog # 07933) or CryoStor® CS10 (Catalog # 07930) and stored at -135°C.

2. Day 0:
   a. Prepare fresh complete ImmuoCult™-XF T Cell Expansion Medium as follows:
      Add cytokines (e.g. Human Recombinant IL-2; Catalog #78036) to ImmuoCult™-XF T Cell Expansion Medium. Mix thoroughly.
      NOTE: Complete ImmuoCult™-XF T Cell Expansion Medium must be prepared fresh on each day of use.
   b. Seed viable human T cells (prepared in step 1) in fresh complete ImmuoCult™-XF T Cell Expansion Medium (prepared in step 2a) at 1 x 10^6 cells/mL.

3. To activate T cells, add 25 µL/mL of ImmuoCult™ Human CD3/CD28 T Cell Activator to the cell suspension. Incubate cells at 37°C and 5% CO₂ for up to 3 days.

4. To expand T cells (after 3 days of activation), perform a viable cell count and adjust the viable cell density every 2 - 3 days by adding fresh complete ImmuoCult™-XF T Cell Expansion Medium to the cell suspension.
   NOTE: For recommended cell densities, refer to the Product Information Sheet for ImmuoCult™-XF T Cell Expansion Medium (Document #DX20347), available at www.stemcell.com or contact us to request a copy.

5. Incubate cells at 37°C and 5% CO₂ until the desired cell number is obtained or for up to 12 days.

6. For longer-term expansion (> 12 days) of human T cells:
   a. Harvest and resuspend the expanded T cells at 1 x 10^6 cells/mL in fresh complete ImmuoCult™-XF T Cell Expansion Medium.
   b. Restimulate by adding 25 µL/mL of ImmuoCult™ Human CD3/CD28 T Cell Activator.
c. Incubate at 37°C and 5% CO₂. Every 2 - 3 days adjust cell density by adding fresh complete ImmunoCult™-XF T Cell Expansion Medium.
NOTE: Ensure to add fresh complete medium every 2 - 3 days; do not wait more than 3 days between medium additions.

RELATED PRODUCTS
For related products, including specialized culture and storage media, supplements, antibodies, cytokines, and small molecules, visit www.stemcell.com/TCellEngineering or contact us at techsupport@stemcell.com.

![FIGURE 1. Activated Morphology of Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator
Human T cells isolated using EasySep™ Human T Cell Isolation Kit (Catalog #17951), stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator, and cultured in complete ImmunoCult™-XF T Cell Expansion Medium.](image1.png)

![FIGURE 2. Activation of EasySep™-Isolated Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator
EasySep™-isolated human T cells were stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator and cultured in complete ImmunoCult™-XF T Cell Expansion Medium. Activation of viable CD3+ T cells was assessed by CD25 expression using flow cytometry. On day 0, the frequency of CD25-positive cells was (A) 5.6 ± 2.4% (mean ± SD). Following 3 days of culture, the frequency of CD25-positive cells was (B) 75.4 ± 13.8% (mean ± SD) when stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator.](image2.png)
FIGURE 3. Robust Human T Cell Expansion with ImmunoCult™ Human CD3/CD28 T Cell Activator
EasySep™-isolated human T cells were expanded over 12 days with ImmunoCult™ Human CD3/CD28 T Cell Activator in ImmunoCult™-XF T Cell Expansion Medium supplemented with Human Recombinant IL-2. On day 0, 1 x 10^6 EasySep™-isolated human T cells were stimulated with 25 µL of ImmunoCult™ Human CD3/CD28 T Cell Activator in ImmunoCult™-XF T Cell Expansion Medium supplemented with 10 ng/mL Human Recombinant IL-2. On days 3, 5, 7, and 10, viable cells were counted and fresh medium supplemented with IL-2 was added. No additional ImmunoCult™ Human CD3/CD28 T Cell Activator was added during the 12-day culture period (mean ± SD in 6 experiments with 3 donors).

Notes and Tips
- This is a general protocol for using ImmunoCult™ Human CD3/CD28 T Cell Activator. Depending on the experimental objectives, optimization may be required (e.g. cell seeding density or cytokine concentration) for optimal cell growth.
- Activated T cells can be used for gene editing, usually 2 - 3 days after activation; the optimal activation period may vary with different gene editing approaches.